Private company

Molecular Templates, Inc.

In its 2024 annual report the company says: “Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer.”5 It is headquartered in South San Francisco, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE3
  • Business address9301 Amberglen Blvd, Suite 100, Austin, Tx 787293
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900VZKP6N0B8U5F612
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 34365902

See how the biggest companies compare on our leaderboards

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. Molecular utilizes its proprietary biologic drug platform to design and generate ETBs, which Molecular believes provide a differentiated mechanism of action that may be beneficial in patients resistant to currently available cancer therapeutics. ETBs use a genetically engineered version of the SLTA, a ribosome inactivating bacterial protein. In its wild-type form, SLTA is thought to induce its own entry into a cell when proximal to the cell surface membrane, self-route to the cytosol, and enzymatically and irreversibly shut down protein synthesis via ribosome inactivation. SLTA is normally coupled to its cognate Shiga-like Toxin B subunit (“SLTB”) to target the CD77 cell surface marker, a non-internalizing glycosph…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-316.3%Operating margin6
-311.7%Net margin6
67.6%Revenue growth, 20197
-67.4%Return on equity8
0.03×Debt to equity6
-$34.9MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2019

  • Research and development100¢$50.5M

Out of $22.3M in revenue.76 The company lost money this year.

Financial statements

Revenue97$22.3M in 2019+556% since 2017
0$10.0M$20.0M$30.0M2017: $3.4M$3.4M20172018: $13.3M$13.3M2018+291%2019: $22.3M$22.3M2019+68%
Operating income1076-$70.4M in 2019+295% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$17.8M-$17.8M20172018: -$31.0M-$31.0M2018+74%2019: -$70.4M-$70.4M2019+127%
Net income1076-$69.4M in 2019+200% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$23.1M-$23.1M20172018: -$30.3M-$30.3M2018+31%2019: -$69.4M-$69.4M2019+129%
Fiscal year201720182019
Revenue$3.4M9$13.3M7$22.3M7
Research and development$9.5M10$30.2M7$50.5M6
Operating expenses
Operating income-$17.8M10-$31.0M7-$70.4M6
Interest$853.0K9
Income before tax
Income tax$010$07$06
Net income-$23.1M10-$30.3M7-$69.4M6
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Molecular Templates, Inc. with another company

Corporate structure

Molecular Templates, Inc. sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Molecular Templates, Inc.

  • SILVERARC CAPITAL MANAGEMENT, LLC Filed SCHEDULE 13G/A on Molecular Templates, Inc., latest Feb 12, 2025 (2 filings since Feb 14, 2024)
  • BB Biotech Filed SC 13G/A on Molecular Templates, Inc., latest Nov 18, 2024 (4 filings since Feb 11, 2022)
  • BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Molecular Templates, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
  • Adage Capital Management, L.P. Filed SC 13G/A on Molecular Templates, Inc., latest Nov 12, 2024
  • Longitude Capital Partners III, LLC Filed SC 13D/A on Molecular Templates, Inc., latest Apr 29, 2024 (3 filings since Feb 14, 2023)
  • SANTE HEALTH VENTURES I LP Filed SC 13D/A on Molecular Templates, Inc., latest Apr 2, 2024
  • K2 HealthVentures Equity Trust LLC Filed SC 13G/A on Molecular Templates, Inc., latest Feb 14, 2024 (2 filings since Jun 26, 2023)
  • Laurence W. Lytton Filed SC 13G/A on Molecular Templates, Inc., latest Feb 14, 2024 (2 filings since Jul 20, 2023)
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G on Molecular Templates, Inc., latest Jul 18, 2023
  • PICTET ASSET MANAGEMENT SA Filed SC 13G on Molecular Templates, Inc., latest Feb 3, 2023 (2 filings since Feb 10, 2022)
  • Molecular Templates, Inc. South San Francisco, California, United States
    • Molecular Templates OpCo, Inc. Subsidiary · Delaware, United States
    • THLD Enterprises (UK), Limited Subsidiary · United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Molecular Templates, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$34.4M13 Dec 31, 2023$36.0M13 Dec 31, 2022−4.3%
Accumulated depreciation$27.0M13 Dec 31, 2023$21.3M13 Dec 31, 2022+26.7%
Property and equipment, net$7.4M13 Dec 31, 2023$14.6M13 Dec 31, 2022−49.5%
Operating-lease assets (leased space)$9.2M13 Dec 31, 2023$11.1M13 Dec 31, 2022−17.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.5M13 Dec 31, 2023$32.2M13 Dec 31, 2022−64.2%
Marketable securities, current$28.9M13 Dec 31, 2022$118.1M14 Dec 31, 2021−75.6%
Marketable securities, non-current$014 Dec 31, 2022$9.0M14 Dec 31, 2021−100.0%
Debt securities available for sale$58.9M14 Dec 31, 2022$152.1M14 Dec 31, 2021−61.3%

Leadership

Who has led Molecular Templates, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Harold E. Selick2006–2016

President

  1. John G. Curd2007–2011

Chief financial officer

  1. Janet I. Swearson2006
  2. Adam D. Cutler2017
  3. Sean McLennan2021
  4. Jason S. Kim2024

Chief operating officer

  1. Michael S. Ostrach2006
  2. Stewart M. Kroll2016
2010201520202025
Board members and other officers (31)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorCorsee E. Sanders named Jul 31, 202353
  • DirectorDavid E. Hoffmann named Jul 31, 202353

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Molecular Templates OpCo, Inc. Delaware4
  • THLD Enterprises (UK), Limited United Kingdom4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • THRESHOLD PHARMACEUTICALS INCAug 27, 2002 to Aug 1, 20173

Timeline

  1. Apr 24, 20258-K Entered a material agreement; Bankruptcy or receivership; New debt or obligation54
  2. Feb 26, 20258-K Entered a material agreement; New debt or obligation; Change to shareholders' rights55
  3. Jan 2, 20258-K Executive or director change; Other events56
  4. Dec 19, 20248-K Listing notice or transfer57
  5. Dec 4, 20248-K Executive or director change58
  6. Dec 4, 20248-K Shareholder vote59
  7. Nov 26, 20248-K Listing notice or transfer; Shareholder vote; Other events60
  8. Oct 11, 20248-K Exit or restructuring costs61
  9. Oct 4, 20248-K Exit or restructuring costs62
  10. Sep 27, 20248-K Shareholder vote63
  11. Aug 14, 20248-K Results of operations64
  12. Jun 3, 20248-K Other events65
  13. Mar 15, 2006New chief executive Harold E. Selick becomes CEO15

Calendar

When it reported results

  1. Aug 14, 2024Reported quarterly or annual results64
  2. May 15, 2024Reported quarterly or annual results66
  3. Mar 29, 2024Reported quarterly or annual results67
  4. Nov 13, 2023Reported quarterly or annual results68
  5. Aug 10, 2023Reported quarterly or annual results69
  6. May 15, 2023Reported quarterly or annual results70
  7. Mar 31, 2023Reported quarterly or annual results71
  8. Nov 10, 2022Reported quarterly or annual results72

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

157 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 47 major events, 44 insider forms, 24 large holders, 1 private raises, 27 other. The latest 20:

  1. May 22, 202525-NSE EDGAR
  2. Apr 24, 20258-K EDGAR
  3. Feb 26, 20258-K EDGAR
  4. Feb 12, 2025SCHEDULE 13G/A EDGAR
  5. Jan 2, 20258-K EDGAR
  6. Dec 19, 20248-K EDGAR
  7. Dec 4, 2024DEFA14A EDGAR
  8. Dec 4, 20248-K EDGAR
  9. Dec 4, 20248-K EDGAR
  10. Nov 26, 2024DEFA14A EDGAR
  11. Nov 26, 20248-K EDGAR
  12. Nov 18, 2024SC 13G/A EDGAR
  13. Nov 18, 20244 EDGAR
  14. Nov 15, 2024NT 10-Q EDGAR
  15. Nov 14, 2024SC 13G/A AMENDMENT NO. 7 TO SCHEDULE 13G EDGAR
  16. Nov 12, 2024SC 13G/A MOLECULAR TEMPLATES, INC. EDGAR
  17. Oct 28, 2024DEF 14A EDGAR
  18. Oct 17, 2024PRE 14A EDGAR
  19. Oct 11, 20248-K EDGAR
  20. Oct 4, 20248-K EDGAR

The 157 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 11 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 14, 2024BB BIOTECH AG10% ownerSale1,279,820$0.66$844.7KForm 4
Apr 2, 2024BIOTECH TARGET N V10% ownerBuy250,000$2.35$587.5KForm 4
Jul 17, 2023BB BIOTECH AG10% ownerBuy4,255,319$0.47$2.0MForm 4
Jun 16, 2022McLennan SeanSee remarksBuy30,000$0.82$24.6KForm 4
Jun 15, 2022LALANDE KEVIN M.DirectorBuy62,000$0.89$55.2KForm 4
Jun 15, 2022Cunningham Joe H10% ownerBuy62,000$0.89$55.2KForm 4
Jun 14, 2022LALANDE KEVIN M.DirectorBuy60,000$0.87$52.2KForm 4
Jun 14, 2022Cunningham Joe H10% ownerBuy60,000$0.87$52.2KForm 4
Jun 13, 2022LALANDE KEVIN M.DirectorBuy100,000$0.91$91.0KForm 4
Jun 13, 2022Cunningham Joe H10% ownerBuy100,000$0.91$91.0KForm 4
May 16, 2022BIOTECH TARGET N V10% ownerBuy200,000$1.18$236.0KForm 4
Jan 6, 2022BB BIOTECH AG10% ownerBuy200,000$4.04$808.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 17, 2023Raised $20 million in a private offering of equity Form D: $90.7 million offered in all Form D

SEC filer profile

How Molecular Templates, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMolecular Templates, Inc.1
  • CIK0001183765
  • Employer ID (EIN)94-34095961
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address9301 Amberglen Blvd, Suite 100, Austin, TX 787291
  • Phone512 896 15551
  • Shares outstanding6,583,880 as of Aug 9, 202412
  • Public float$18.0M as of Jun 30, 202383
  • On EDGAR sinceAug 27, 20021
  • Filings1,223 in all: 4 (427), 8-K (258), SC 13G/A (93), 3 (63), 10-Q (59), SC 13G (37), DEF 14A (22), 10-K (20)1
    All 49 form types

    S-8 (20), 4/A (19), CORRESP (18), UPLOAD (17), 5 (16), 424B5 (14), EFFECT (13), S-3 (13), SC 13D/A (10), 424B3 (9), S-1/A (9), CT ORDER (8), DEFA14A (8), 3/A (7), 425 (6), D (5), PRE 14A (5), SC TO-I/A (5), 10-K/A (4), ARS (4), S-3/A (4), NT 10-Q (3), REGDEX (3), SC 13D (3), 424B4 (2), 8-K/A (2), S-1 (2), SC TO-I (2), 10-Q/A (1), 25-NSE (1), 5/A (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), D/A (1), PRER14A (1), S-3MEF (1), S-4 (1), S-4/A (1), S-8 POS (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 29, 2024
    Quarterly report (10-Q) Aug 14, 2024
    Proxy statement (DEF 14A) Oct 28, 2024
    Latest 8-K (8-K) Apr 24, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
    SEC EDGAROther events
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83